← All organizations
Highest phase reached
Phase 4
First clinical trial
Dec 31, 2006Last known activity
Mar 7, 2022
Timeline
1960s
- Jun 1, 1963
Agenzia Italiana del Farmaco— Founded
Drugs by trial phase (40 distinct, 24 trials)
Phase 4 (8 own, 0 via acquisition)
Phase 3 (30 own, 0 via acquisition)
Phase 2 (1 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
- Amyotrophic Lateral Sclerosis
- Arthritis
- Arthritis, Juvenile
- Ascites
- Ataxia
- Breast Neoplasms
- Bronchial Spasm
- Cerebellar Ataxia
- Colitis
- Colitis, Ulcerative
- Diabetes Mellitus
- Fibrosis
- Gastroenteritis
- Glomerulosclerosis, Focal Segmental
- Hypertension
- Hypertrophy
- Hypertrophy, Left Ventricular
- Infant, Premature, Diseases
- Liver Cirrhosis
- Motor Neuron Disease
- Nephrosis
- Nephrosis, Lipoid
- Nephrotic Syndrome
- Parkinson Disease
- Polycythemia
- Polycythemia Vera
- Pulmonary Alveolar Proteinosis
- Respiratory Sounds
- Respiratory Tract Infections
- Sarcoidosis
- Sarcoidosis, Pulmonary
- Sclerosis
- Syndrome
- Ulcer
- Vomiting
Recent trials (24)
- NCT05321394CollaboratorPhase 3Mar 7, 2022
- NCT05205759CollaboratorPhase 3Dec 9, 2021
- NCT04716556CollaboratorN/AJul 16, 2020
- NCT06770894CollaboratorPhase 3Sep 24, 2019
- NCT03728478CollaboratorPhase 3Mar 31, 2019
- NCT05728632CollaboratorPhase 3Jan 1, 2019
- NCT03227328CollaboratorPhase 3Aug 2, 2017
- NCT03151525CollaboratorPhase 4May 8, 2017
- NCT02741947CollaboratorPhase 4Apr 1, 2014
- NCT01257672CollaboratorPhase 3Jul 1, 2011
- NCT01288794CollaboratorPhase 4Mar 1, 2011
- NCT01265342CollaboratorPhase 4Oct 1, 2010
- NCT01104649CollaboratorPhase 2/Phase 3Apr 1, 2010
- NCT00901511CollaboratorPhase 2/Phase 3Jul 1, 2009
- NCT00985322CollaboratorPhase 3May 1, 2009
Details
- Founded
- Rome, IT Jun 1, 1963
- Last known activity
- Mar 7, 2022